UCB Logo

UCB

A biopharmaceutical company focused on severe diseases in neurology and immunology.

UCB | BR

Overview

Corporate Details

ISIN(s):
BE0002730118 (+5 more)
LEI:
2138008J191VLSGY5A09
Country:
Belgium
Address:
ALLÉE DE LA RECHERCHE 60, 1070 ANDERLECHT

Description

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-11-08 20:00
241108 - PB Transparantieverklaring BlackRock.pdf
Dutch PDF 207.3 KB
2024-10-10 20:00
ENG.pdf
English PDF 138.1 KB
2024-10-10 20:00
FR.pdf
French PDF 190.1 KB
2024-10-10 20:00
NL.pdf
Dutch PDF 207.4 KB
2024-10-09 20:00
091024 - PR Transparency notification BlackRock.pdf
English PDF 138.7 KB
2024-10-09 20:00
091024 - CdP Notification de transparence BR.pdf
French PDF 191.1 KB
2024-10-09 20:00
091024 - PB Transparantieverklaring BlackRock.pdf
Dutch PDF 207.7 KB
2024-10-03 20:00
031024 - PR Transparency notification BlackRock (2).pdf
English PDF 137.9 KB
2024-10-03 20:00
031024 - CdP Notification de transparence BlackRock.pdf
French PDF 188.6 KB
2024-10-03 20:00
031024 - PB Transparantieverklaring BlackRock.pdf
Dutch PDF 207.0 KB
2024-10-01 20:00
011024 - PR Transparency notification BlackRock.pdf
English PDF 137.6 KB
2024-10-01 20:00
011024 - CdP Notification de transparence BlackRock.pdf
French PDF 188.5 KB
2024-10-01 20:00
011024 - PB Transparantieverklaring BlackRock.pdf
Dutch PDF 206.5 KB
2024-09-30 20:00
300924 - PR Transparency notification BlackRock (2).pdf
English PDF 137.0 KB
2024-09-30 20:00
300924 - CdP Notification de transparence BlackRock.pdf
French PDF 189.2 KB

Automate Your Workflow. Get a real-time feed of all UCB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for UCB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for UCB via our API.

Get Historical Data →

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.